Topic
Glucagon-like peptide-1 receptor agonists, a drug class including Ozempic and Wegovy, used to treat type 2 diabetes and obesity.
Business Group on Health's survey finds at least 10% of employer plans covering GLP-1 weight-loss drugs likely to drop them in 2027. About two-thirds of private employer plans covered them in 2026, and each exit now leaves workers to pay cash or stop.
Reality
Health Transformation Alliance data show 83% of Type 2 diabetes patients with no GLP-1 gains stayed on therapy, against 94% of responders. For employers setting 2027 terms, poor responders mostly do not leave the drug on their own.
Reality
Lilly's brenipatide, tested for alcohol use disorder, has a half-life of 9-12 days against 5-7 for approved GLP-1 drugs, Nature reported. Kariya has early Parkinson's data on KP405. Baseline plans a phase III of BT-001 in early 2027.
Reality
Exponential View says GLP-1 sales reached $76 billion in 2025, ahead of its own $63 billion estimate for generative AI. The $13 billion lead rests on that estimate, and the retention studies the piece cites show heavy attrition.
Reality
Novo Nordisk and Eli Lilly say patients on their GLP-1 drugs measured two to three years younger on molecular aging clocks than those on placebo. The size of that drop swings with which clock is used and which organ it reads.
Reality
Business Group on Health projects employer drug costs will rise 12% in 2026, faster than overall health costs, as GLP-1 and specialty use grows. For 2027 renewals, total pharmacy spend is a better test of a PBM than its rebate guarantee, though most PBM reports are not built to show it.
Reality
Japan's obesity society warned cosmetic GLP-1 users of side-effect risks, as 35 of about 950 Mounjaro side-effect reports involved dieting or cosmetic use. The health ministry separately said the drugs should not be used casually as weight-loss pills.
Reality
Sun Life US says high-dollar claims involving GLP-1 drugs rose 24% in a year and wants employers to treat coverage as cardiometabolic risk. Its data shows where catastrophic costs cluster, but any payoff from coverage depends on adherence, cost-sharing and tenure.
Reality
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
Prescribing has outrun the approval label for US children aged 8 to 11 with obesity. The trial behind the benefit claim followed them for 68 weeks. Those 68 weeks are the entire developmental record so far.
Reality
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
Mercer's survey of 1,800 employers puts health costs per worker up 8.2% in 2027, the steepest rise since 2003, and the $3.48 an hour employers already spend on health insurance comes out of the same budget as pay.
Reality
A University of Pennsylvania group read five years of GLP-1 discussion from nearly 70,000 Reddit users and came out with two symptom families worth a real study, plus a nausea signal that shows the method finds what is already known.
Reality
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Reality
An NIH-funded UC Berkeley team dosed old, healthy female mice, then fed a second group 24% fewer calories to match what the drug's appetite suppression achieved. The drug still did more on memory and blood sugar.
Reality
Samsung Biologics is paying for peptide capacity with new stock rather than debt, and the arithmetic inside its own 15.4 trillion won decade plan says the antibody campus, not GLP-1, still gets most of the money.
Reality